Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00158314 · ClinicalTrials.gov registry record · Phase 1
Cognitive Behavioral Therapy for Treatment of Pathological Gambling
A Phase 1 study, sponsored by UConn Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 231
- Enrollment target
NCT00158314: Completed Phase 1 study, sponsored by UConn Health.
NCT00158314 is a Phase 1 study that has completed, run by UConn Health. The registered enrollment target is 231 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (285% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00158314, a Phase 1 study, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 231 participants
- Enrollment target
Study Summary
This study will determine the effectiveness and cost-effectiveness of three different treatment strategies in reducing gambling behaviors.
Interventions
- BEHAVIORAL Cognitive behavioral therapy
- BEHAVIORAL Referral to Gamblers Anonymous
- BEHAVIORAL Cognitive behavioral self-help manual
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 1998-03 |
| Est. Completion | 2003-11 |
| Phase | Phase 1 |
What the finished NCT00158314 record still lists
NCT00158314 is an interventional study that assigns participants to a tested intervention. The registered 231 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (285% higher).
The record links to 0 conditions, and to 3 interventions - of which Cognitive behavioral therapy is the first listed.
NCT00158314 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00158314 about?
NCT00158314 is a clinical study titled "Cognitive Behavioral Therapy for Treatment of Pathological Gambling". This study will determine the effectiveness and cost-effectiveness of three different treatment strategies in reducing gambling behaviors.
What is the current status of trial NCT00158314?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 231 participants. The study started on 1998-03. Estimated completion is 2003-11.
What interventions are being tested in trial NCT00158314?
The interventions under investigation include: Cognitive behavioral therapy (BEHAVIORAL), Referral to Gamblers Anonymous (BEHAVIORAL), Cognitive behavioral self-help manual (BEHAVIORAL).
Who is sponsoring clinical trial NCT00158314?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00158314's enrollment target sits among peer trials
231 217th of 2000 higher than 1,782 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04077099 · 231 participants · Phase 1
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
- NCT05019495 · 231 participants · NA
Optimizing Tobacco Treatment Delivery for People Living With HIV
- NCT06023589 · 231 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
- NCT06734351 · 231 participants · Phase 3
A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia